Bispecific antibodies can do what few other therapeutics can: guide immune cells to malignant tissue, block multiple signaling pathways at once, or deliver cytotoxic payloads with high precision. But engineering a stable protein complex with two distinct binding domains is hard. Light-chain mispairing, homodimer contaminants, bespoke purification workflows, and formulation problems can stall promising candidates long before they reach the clinic.

In this white paper, we describe how the B-Body® bispecific platform, engineered by Invenra and made available through Twist Bioscience, reduces these risks. Drawing on data from more than 15,500 B-Body constructs, it shows how an IgG-like framework with built-in light-chain pairing supports plug-and-play Fab and Fc combinations, high-throughput screening, and standard mAb manufacturing processes.

Covered in this white paper: